Covered recipient · General Payments record
KI YOUNG CHUNG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$10,646.94
157 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,870.00 | 2 |
| Food and Beverage | $3,775.07 | 144 |
| Long term medical supply or device loan | $581.83 | 6 |
| Education | $420.04 | 5 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KI YOUNG CHUNG
NPI 1336110113 · CMS profile ID 15168
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SPARTANBURG, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
157 matching records · $10,646.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 157.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. | $21.81 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242669458 | CMS |
| Merck Sharp & Dohme LLC | $34.34 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238303519 | CMS |
| PFIZER INC. | $20.54 | 08/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231674365 | CMS |
| Daiichi Sankyo Inc. | $23.19 | 08/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197018177 | CMS |
| Gilead Sciences, Inc. | $121.87 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234387552 | CMS |
| Celgene Corporation | $22.25 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184570577 | CMS |
| Novartis Pharmaceuticals Corporation | $8.69 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128971 | CMS |
| GlaxoSmithKline, LLC. | $67.00 | 07/29/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190386259 | CMS |
| Pharmacosmos Therapeutics Inc. | $15.95 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250726369 | CMS |
| Caris MPI, Inc. | $33.39 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234279298 | CMS |
| Azurity Pharmaceuticals, Inc. | $18.72 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242669456 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,820.00 | 07/22/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184570561 | CMS |
| Lilly USA, LLC | $13.01 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186664143 | CMS |
| Rigel Pharmaceuticals, Inc. | $19.86 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247375696 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.99 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206282670 | CMS |
| Aimmune Therapeutics, Inc. | $14.36 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249717325 | CMS |
| Lilly USA, LLC | $23.17 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186746579 | CMS |
| Eisai Inc. | $18.00 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244491920 | CMS |
| Novartis Pharmaceuticals Corporation | $17.95 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128969 | CMS |
| PFIZER INC. | $21.91 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231583521 | CMS |
| Janssen Biotech, Inc. | $18.70 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174782059 | CMS |
| Merck Sharp & Dohme LLC | $21.36 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238173084 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.16 | 07/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184570573 | CMS |
| Janssen Biotech, Inc. | $24.71 | 07/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174783581 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $19.83 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225497174 | CMS |
| Genentech USA, Inc. | $53.45 | 06/26/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211531662 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.62 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206364820 | CMS |
| ABBVIE INC. | $16.96 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201663929 | CMS |
| Janssen Biotech, Inc. | $20.32 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174781784 | CMS |
| Gilead Sciences, Inc. | $31.20 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234431686 | CMS |
| Merck Sharp & Dohme LLC | $22.05 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238349750 | CMS |
| Daiichi Sankyo Inc. | $17.46 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197101713 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 06/12/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128917 | CMS |
| Novartis Pharmaceuticals Corporation | $24.04 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128965 | CMS |
| Novartis Pharmaceuticals Corporation | $0.88 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128967 | CMS |
| Merck Sharp & Dohme LLC | $32.97 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238173112 | CMS |
| Gilead Sciences, Inc. | $29.20 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234443201 | CMS |
| Gilead Sciences, Inc. | $0.28 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234610821 | CMS |
| PFIZER INC. | $18.90 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231627433 | CMS |
| TOLMAR, INC. | $33.73 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237005213 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.36 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206882467 | CMS |
| Genmab U.S., Inc. | $121.87 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235921446 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.38 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206220232 | CMS |
| Eisai Inc. | $20.50 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244491918 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,050.00 | 05/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207304282 | CMS |
| Daiichi Sankyo Inc. | $23.34 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197098723 | CMS |
| Janssen Biotech, Inc. | $99.95 | 05/15/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174782130 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 05/15/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200128913 | CMS |
| TAIHO ONCOLOGY, INC. | $20.41 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211407581 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.93 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223839981 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $627,547.51 | 52 |
| PY2024 | Principal investigator | $1,192,196.50 | 37 |
| PY2023 | Principal investigator | $730,279.90 | 32 |
| PY2022 | Principal investigator | $1,530,194.34 | 54 |
| PY2021 | Principal investigator | $106,782.01 | 27 |
| PY2020 | Principal investigator | $142,607.48 | 58 |
| PY2019 | Recipient | $44.41 | 1 |
| PY2019 | Principal investigator | $342,856.70 | 71 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Coherus Oncology, Inc. | $7,308.00 | 12/23/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | CHS11402 | No dispute reported | 06/30/2026 | 1235252521 |
| Principal investigator 1 | PFIZER INC. | $60,090.00 | 12/05/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228738646 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,850.00 | 10/29/2025 | Covered Recipient Teaching Hospital Ph Patewood Hospital | A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer | No dispute reported | 06/30/2026 | 1185539417 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,109.85 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995014 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $29.30 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995016 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.20 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995018 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $373.12 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995020 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $79.92 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995022 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $584.00 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995024 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $916.05 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995026 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $72.32 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995028 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,448.55 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995030 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.00 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995032 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $25.00 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995034 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.80 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995036 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.00 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995038 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $56.40 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995040 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $52.50 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995042 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $61.50 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995044 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11.50 | 10/27/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220995046 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $325.57 | 10/01/2025 | Non-covered Recipient Entity Institute For Translational Oncology Research | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220643194 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $3,404.00 | 09/12/2025 | Covered Recipient Teaching Hospital Oconee Memorial Hospital | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | No dispute reported | 06/30/2026 | 1184285761 |
| Principal investigator 1 | BioNTech SE | $270.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | BNT321-02 | No dispute reported | 06/30/2026 | 1249018400 |
| Principal investigator 1 | BioNTech SE | $90.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | BNT321-02 | No dispute reported | 06/30/2026 | 1249018402 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | BNT321-02 | No dispute reported | 06/30/2026 | 1249018404 |
| Principal investigator 1 | BioNTech SE | $1,994.00 | 07/14/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | BNT321-02 | No dispute reported | 06/30/2026 | 1249018406 |
| Principal investigator 1 | BioNTech SE | $250.00 | 07/14/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | BNT321-02 | No dispute reported | 06/30/2026 | 1249018408 |
| Principal investigator 1 | Coherus Oncology, Inc. | $20,200.00 | 06/26/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | CHS38802 | No dispute reported | 06/30/2026 | 1235252559 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 05/20/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228755061 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/20/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228755812 |
| Principal investigator 1 | PFIZER INC. | $21,880.00 | 05/19/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228756704 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/19/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228757865 |
| Principal investigator 1 | Coherus Oncology, Inc. | $21,700.00 | 05/13/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | CHS11402 | No dispute reported | 06/30/2026 | 1235252517 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,282.00 | 04/04/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176544941 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 03/20/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228755000 |
| Principal investigator 1 | PFIZER INC. | $12,467.36 | 03/20/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228755901 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $9,651.33 | 03/19/2025 | Covered Recipient Teaching Hospital Oconee Memorial Hospital | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | No dispute reported | 06/30/2026 | 1184285759 |
| Principal investigator 1 | PFIZER INC. | $12,467.36 | 03/19/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228757203 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 03/19/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228758217 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,246.00 | 03/07/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | No dispute reported | 06/30/2026 | 1234179998 |
| Principal investigator 1 | PFIZER INC. | $6,233.68 | 02/25/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228755394 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 02/25/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228758013 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 02/25/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228758017 |
| Principal investigator 1 | PFIZER INC. | $6,233.68 | 02/25/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228758191 |
| Principal investigator 1 | PFIZER INC. | $6,233.68 | 02/24/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228720041 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 02/24/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228756707 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 02/20/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228743565 |
| Principal investigator 1 | PFIZER INC. | $6,233.68 | 02/20/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228754983 |
| Principal investigator 1 | PFIZER INC. | $12,467.36 | 01/14/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228758834 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 01/14/2025 | Non-covered Recipient Entity Prisma Health Cancer Institute | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228759165 |
| Principal investigator 1 | PFIZER INC. | $21,998.34 | 01/13/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228754553 |
| Principal investigator 1 | PFIZER INC. | $12,467.36 | 01/13/2025 | Covered Recipient Teaching Hospital Ghs Greenville Memorial Hospital | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228754598 |